STAAR Surgical Releases Q2 Results Following News of Intended Acquisition by Alcon

Published on August 7, 2025
LAKE FOREST, Calif.—STAAR Surgical Company (NASDAQ: STAA), a leading developer of phakic intraocular lenses with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, has announced 2025 second quarter financial results for the period ending June 27, 2025. Net sales for the company were reported at $44.3 million for the second quarter, a year-over-year decline of 55 percent versus $99.0 million for the same period last year, but were up slightly versus Q1 sales of 42.6 million.
Continue reading on website
Other news

Another drop in the presbyopia bucket: Dr Bloomenstein shares his excitement for the FDA approval of Vizz

August 6, 2025
With FDA approval of LENZ Therapeutics’ Vizz (LNZ100), optometrists now have a daily, non-invasive treatment option for presbyopia, giving patients more freedom and clinicians greater flexibility in care.

How can myopia be controlled when only a small percentage of doctors attempt to control it?

August 7, 2025
Specialty care is always needed in any field, and myopia control is no exception.